Tofersen for SOD-1-associated amyotrophic lateral sclerosis

Affiliations

¹ Unit Neurology, Psychiatry, Ophthalmology, Federal Institute for Drugs and Medical Devices, Bonn, Germany; Central Nervous System Working Party, European Medicines Agency, Amsterdam, Netherlands. Electronic address: marion.haberkamp@bfarm.de.
² Unit Neurology, Psychiatry, Ophthalmology, Federal Institute for Drugs and Medical Devices, Bonn, Germany.
³ Office of Therapies for Neurological and Psychiatric Disorders, European Medicines Agency, Amsterdam, Netherlands.
⁴ Division Licensing, Federal Institute for Drugs and Medical Devices, Bonn, Germany; Committee of Medicinal Products for Human Use, European Medicines Agency, Amsterdam, Netherlands.

Marion Haberkamp et al. Lancet Neurol. 2024 Aug.

. 2024 Aug;23(8):772-773.

doi: 10.1016/S1474-4422(24)00259-X.

¹ Unit Neurology, Psychiatry, Ophthalmology, Federal Institute for Drugs and Medical Devices, Bonn, Germany; Central Nervous System Working Party, European Medicines Agency, Amsterdam, Netherlands. Electronic address: marion.haberkamp@bfarm.de.
² Unit Neurology, Psychiatry, Ophthalmology, Federal Institute for Drugs and Medical Devices, Bonn, Germany.
³ Office of Therapies for Neurological and Psychiatric Disorders, European Medicines Agency, Amsterdam, Netherlands.
⁴ Division Licensing, Federal Institute for Drugs and Medical Devices, Bonn, Germany; Committee of Medicinal Products for Human Use, European Medicines Agency, Amsterdam, Netherlands.

No abstract available

Publication types